SABRINA WONG: Open Payments
NPI 1629702162 · CHANDLER, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,248 in 47 payments from 16 companies in 2025. Trend: 2023 $0 · 2024 $772 · 2025 $1,248
Food & beverage: $1,248
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $361 |
| Novartis Pharmaceuticals Corporation | 5 | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $112 |
| GlaxoSmithKline, LLC. | 5 | $107 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $99 |
| Incyte Corporation | 1 | $91 |
| GENZYME CORPORATION | 3 | $70 |
| Regeneron Healthcare Solutions, Inc. | 2 | $53 |
| Amgen Inc. | 3 | $45 |
| Grifols USA, LLC | 2 | $37 |
Products named: BREZTRI, DUPIXENT, NEFFY, Opzelura, FASENRA, TEZSPIRE, NUCALA, CUVITRU.
Industry payments across AZ — which companies pay providers there.
